Adipotide
Adipotide is an experimental peptide conjugate targeting the blood supply of fat tissue. Its evidence is primarily preclinical primate research.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
Adipotide denotes the vascular-targeting peptide conjugate defined in the primate study. A research or marketed product may not match that study identity.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The primate study examined weight and metabolic changes and reported reversible proximal renal-tubule changes.
- Adipose-targeting peptidomimetic in obese primatesAnimal study2011
U.S. National Library of Medicine (PubMed)
Accessed:
Research gaps
- ·Animal findings do not establish an obesity treatment for people. A first-in-human cancer study was registered but provides no robust efficacy finding here.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
The approach combines targeting of adipose vasculature with a cell-damaging peptide segment.
- Adipose-targeting peptidomimetic in obese primatesAnimal study2011
U.S. National Library of Medicine (PubMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·The primate study reported reversible proximal renal-tubule injury; the clinical safety profile remains unresolved.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Animal findings do not establish an obesity treatment for people. A first-in-human cancer study was registered but provides no robust efficacy finding here.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Adipose-targeting peptidomimetic in obese primatesAnimal study2011
U.S. National Library of Medicine (PubMed)
Accessed:
Sources
Sources checked: · Version 2
- Adipose-targeting peptidomimetic in obese primatesAnimal study2011
U.S. National Library of Medicine (PubMed)
Accessed:
- ClinicalTrials.gov: NCT01262664 prohibitin-targeting peptide studyStudy registry2010
U.S. National Library of Medicine (ClinicalTrials.gov)
Accessed: